Two commercialized hematology products, Olverembatinib and Lisaftoclax, drive dual-engine growth with strong China market presenceNext-generation BTK protein degrader APG-3288 receives…
January 12, 2026 10:30 ET | Source: BridgeBio Pharma, Inc. - Preliminary unaudited Q4 and Full Year 2025 net Attruby® product…
January 11, 2026 13:00 ET | Source: Krystal Biotech, Inc. Preliminary 4Q 2025 VYJUVEK net revenue of $106 million to…
- Rapidly transforming into a leading global biopharma company January 09, 2026 18:01 ET | Source: Ascendis Pharma COPENHAGEN, Denmark,…
"You never change things by [only] fighting the existing reality. To change something, build a new model that makes the…
January 05, 2026 11:05 ET | Source: Zealand Pharma Press release – No. 1 / 2026 Zealand Pharma to present…
January 02, 2026 16:05 ET | Source: RxSight, Inc. ALISO VIEJO, Calif., Jan. 02, 2026 (GLOBE NEWSWIRE) -- RxSight, Inc.,…
January 02, 2026 16:05 ET | Source: Regeneron Pharmaceuticals, Inc. TARRYTOWN, N.Y., Jan. 02, 2026 (GLOBE NEWSWIRE) -- Regeneron Pharmaceuticals,…
January 02, 2026 16:01 ET | Source: FormFactor, Inc. LIVERMORE, Calif., Jan. 02, 2026 (GLOBE NEWSWIRE) -- FormFactor, Inc. (Nasdaq:…
December 29, 2025 16:30 ET | Source: iRhythm SAN FRANCISCO, Dec. 29, 2025 (GLOBE NEWSWIRE) -- iRhythm Technologies, Inc. (NASDAQ:IRTC),…